11:33 AM EDT, 04/04/2024 (MT Newswires) -- MacroGenics ( MGNX ) shares jumped 33% in recent trading Thursday, a day after the company said it will present updated clinical information in autumn on radiographic progression-free survival from the phase 2 trial of vobra duo in people with metastatic castration-resistant prostate cancer.

The radiographic progression-free survival is the primary endpoint of the study, the company said.

MacroGenics ( MGNX ) expects to provide interim results from the trial, including updated safety and preliminary efficacy data, by May 31.

An abstract containing early interim data with a Jan. 4 cutoff date was not accepted by the American Society of Clinical Oncology for presentation at a meeting starting May 31, the company said.

Price: 18.18, Change: +4.51, Percent Change: +32.99